Persistent Candida conglobata bloodstream infection in a preterm neonate successfully treated by combination therapy with amphotericin B and caspofungin

J Mycol Med. 2017 Jun;27(2):271-276. doi: 10.1016/j.mycmed.2017.01.010. Epub 2017 Feb 9.

Abstract

Fungemia due to uncommon/rare Candida species is an emerging problem of global clinical significance. Here, we describe a case of Candida conglobata bloodstream infection in a preterm neonate. The diagnosis was established by repeated isolation of C. conglobata in blood cultures and by detection of rDNA of the fungus in serum samples. The identity of the isolate as C. conglobata was confirmed by sequencing of ITS region and D1/D2 domains of rDNA. Despite initial treatment with a liposomal amphotericin B (AmBisome) for 7 days, the blood culture remained positive. The neonate was successfully treated by combination therapy with caspofungin for 25 days. To the best of our knowledge, this is the first proven report unequivocally proving the etiologic role of C. conglobata in bloodstream infection.

Keywords: Candida conglobata; Combination therapy; Fungemia; Kuwait.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B / administration & dosage*
  • Antifungal Agents / administration & dosage
  • Candidemia / drug therapy*
  • Candidiasis / drug therapy*
  • Candidiasis / microbiology
  • Caspofungin
  • Catheter-Related Infections / drug therapy
  • Catheter-Related Infections / microbiology
  • Drug Therapy, Combination
  • Echinocandins / administration & dosage*
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases / drug therapy*
  • Infant, Premature, Diseases / microbiology
  • Lipopeptides / administration & dosage*
  • Male
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Amphotericin B
  • Caspofungin